BioSpace News Archive

Tranquis Therapeutics, today announced it presented positive preclinical data on its lead program TQS-168 at the Neuroscience 2021 meeting, which is the annual meeting of the Society for Neuroscience (SfN).

Parthenon Therapeutics today announced a $65 million Series A financing led by Northpond Ventures, Pfizer Ventures, and Taiho Ventures.

A more robust pipeline of novel targets spanning all clinical trial phases and an ongoing focus on therapeutics driven by the biology of aging offers new hope for treating Alzheimer’s disease, and slowing or stopping its progression, according to the Alzheimer’s Drug Discovery Foundation (ADDF).

Inventiva announced that it will host a webcast event focused on NASH with the participation of four Key Opinion Leaders on November 19, 2021 from The Liver Meeting™ 2021, organized by the American Association for the Study of Liver Diseases.

Alpha Teknova, Inc., a leading provider of critical reagents for the development and production of biopharmaceutical products including drug therapies, novel vaccines, and molecular diagnostics, announced that it will report its financial results for the third quarter of 2021 on Wednesday, November 10, 2021, following the close of market.

TRACON Pharmaceuticals (NASDAQ:TCON), today announced financial results for the third quarter ended September 30, 2021.

Adaptive Biotechnologies Corporation today reported financial results for the quarter ended September 30, 2021.

Corcept Therapeutics Incorporated, a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effects of the hormone cortisol, reported its results for the quarter ended September 30, 2021.

Sarepta Therapeutics, Inc. today reported financial results for the third quarter of 2021

Oyster Point Pharma, Inc. (Nasdaq: OYST), today announced that TYRVAYA™ (varenicline solution) Nasal Spray 0.03 mg is now available at U.S. regional wholesalers for distribution to pharmacies. The U.S. Food and Drug Administration (FDA), approved TYRVAYA Nasal Spray for the treatment of the signs and symptoms of dry eye disease on October 15, 2021.